Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Dr Reddy’s Laboratories ( (RDY) ) has issued an update.
Dr. Reddy’s Laboratories announced the scheduling of its 41st Annual General Meeting (AGM) on July 24, 2025, at 11:00 A.M. IST, which will be conducted through video conferencing. The announcement includes details about the e-voting process, which will be available from July 20 to July 23, 2025, providing shareholders with the opportunity to participate and vote on company matters remotely.
The most recent analyst rating on (RDY) stock is a Buy with a $17.40 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories’ strong financial performance is the most significant factor, underscored by consistent revenue growth and profitability. Technical analysis supports a favorable stock trend, although valuation is fair with modest income potential. The absence of earnings call and corporate events data did not impact the overall score.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a pharmaceutical company based in Hyderabad, India. The company is involved in the production and distribution of a wide range of generic medications, active pharmaceutical ingredients, and over-the-counter products, focusing on providing affordable and innovative medicines globally.
Average Trading Volume: 2,030,559
Technical Sentiment Signal: Strong Buy
Current Market Cap: $12.7B
Learn more about RDY stock on TipRanks’ Stock Analysis page.